Over recent years, a class of pharmaceutical interventions known as GLP-1 receptor agonists has revolutionized the management of several chronic health conditions, including obesity, type 2 diabetes, and non-alcoholic fatty liver disease. Medications such as semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (available as Mounjaro and Zepbound) have achieved significant success in promoting weight loss and improving glycemic control for many patients. These drugs function by mimicking the action of glucagon-like peptide-1, a hormone that plays a crucial role in regulating appetite and insulin secretion.
However, the widespread adoption of these appetite-suppressing medications has also brought to light a number of potential drawbacks. A significant proportion of individuals experience adverse gastrointestinal effects, including nausea, vomiting, and diarrhea. Beyond these immediate discomforts, a more complex concern relates to the unintended consequences of drastically reduced caloric intake. When the body consumes fewer calories, it can lead to a decrease in essential nutrient absorption and, importantly, a loss of lean muscle mass. This muscle depletion can, in turn, increase an individual’s susceptibility to frailty, reduce metabolic rate over the long term, and potentially compromise overall functional capacity, raising questions about the sustained health benefits of such interventions.
In light of these challenges, a research team at the University of California, Berkeley, has embarked on an alternative therapeutic strategy aimed at addressing obesity and related metabolic disorders. Rather than focusing on curtailing energy intake, their innovative approach targets the body’s energy expenditure, seeking to enhance metabolic activity and promote the utilization of stored energy reserves. This represents a fundamental shift in the paradigm of metabolic disease treatment, moving from restriction to activation.
The cornerstone of this new research is a molecular entity identified as 5-tetradecyloxy-2-furoic acid, or TOFA. Published in the August 21st edition of the journal Science Advances, the findings detail how TOFA intervenes in the intricate biochemical pathways responsible for lipid synthesis, effectively modulating the production of fats such as cholesterol and triglycerides. Crucially, TOFA also appears to stimulate the expression of genes that are instrumental in prompting cells to tap into fat stores for energy, thereby elevating the body’s overall energy output.
Preclinical investigations conducted with rodent models have yielded encouraging results. In obese mice subjected to TOFA treatment, researchers observed marked improvements in insulin sensitivity and glucose regulation, alongside a reduction in triglyceride levels. Furthermore, indicators of fatty liver disease showed amelioration. A particularly noteworthy outcome was the significant loss of adipose tissue, or body fat, without a corresponding detrimental impact on lean muscle mass. This preservation of muscle is a critical differentiator from other weight-loss strategies that often lead to muscle catabolism.
Explaining the rationale behind their research, Professor Anders Nørre, a leading expert in metabolic biology and nutrition at UC Berkeley and the senior author of the study, articulated the fundamental principles governing body weight. "Body weight responds to two levers: taking in fewer calories, or spending more energy," he stated. "GLP-1s work almost entirely on the first, so we went after the second." This direct comparison highlights the distinct mechanism of action pursued by the Berkeley team.
The compound TOFA itself is not an entirely novel discovery, having been initially identified in the 1970s as a member of a family of molecules known as ACC (acetyl-CoA carboxylase) inhibitors. These compounds are recognized for their ability to reduce the body’s de novo synthesis of lipids. While several ACC inhibitors have progressed through various stages of clinical development, none have yet secured regulatory approval for the treatment of metabolic diseases. A primary hurdle for many of these compounds has been their propensity to elevate triglyceride levels, a factor that can unfortunately increase the risk of cardiovascular complications.
The UC Berkeley researchers, however, observed a unique profile for TOFA. Beyond its capacity to inhibit ACC, TOFA demonstrates an additional and significant action: it activates peroxisome proliferator-activated receptors (PPARs), specifically PPARα and PPARγ. These cellular receptors act as transcriptional regulators, initiating the expression of genes that are pivotal in facilitating the uptake of fatty acids from the bloodstream and their subsequent utilization as an energy source. This dual mechanism—suppressing lipid production while simultaneously promoting lipid utilization—appears to be key to TOFA’s distinctive effects.
In the mouse studies, this combined action led to an increase in energy expenditure by as much as 18%. Intriguingly, this heightened metabolic rate was not accompanied by an increase in physical activity levels or a rise in body temperature, suggesting a more intrinsic enhancement of cellular energy turnover. Moreover, the observed lack of triglyceride elevation, a common side effect of other ACC inhibitors, is hypothesized to stem from TOFA’s integrated modulation of both lipid synthesis and energy metabolism.
Justin Y. Lee, the study’s first author and a postdoctoral researcher at UCSF who conducted the work as a doctoral candidate at Berkeley, elaborated on this synergistic effect. "TOFA appears to engage a coordinated metabolic response," Lee remarked. "It is not simply blocking lipid synthesis. It is also activating energy expenditure pathways that may help the body handle excess lipid and glucose more effectively." This suggests a holistic approach to metabolic regulation, addressing multiple facets of energy balance.
To further elucidate the significance of TOFA’s multifaceted mechanism, the researchers designed an experiment to test whether its effects could be replicated by combining two separate compounds: one designed to inhibit lipid synthesis and another aimed at boosting energy expenditure. The results indicated that this dual-drug approach was less effective in improving overall metabolic health compared to TOFA administered alone. This finding underscores the potential importance of TOFA’s unique, integrated molecular action in achieving its therapeutic benefits.
Recognizing the established efficacy of GLP-1 receptor agonists, the team also investigated the potential for TOFA to be used in conjunction with these existing medications. In their animal models, the combination of TOFA with semaglutide or tirzepatide yielded superior outcomes in terms of body weight reduction, glucose homeostasis, insulin sensitivity, and triglyceride levels than either treatment alone. Professor Nørre characterized this complementary relationship, stating, "In our combination experiments, TOFA worked additively or synergistically with the GLP-1 appetite-suppressing drugs, so we view it as complementary rather than as a replacement." This suggests a potential for enhanced therapeutic efficacy by combining the appetite-suppressing effects of GLP-1 agonists with the energy-expending properties of TOFA.
Despite the promising preclinical data, the researchers are quick to emphasize that TOFA has, to date, only been evaluated in animal models. Its safety profile and efficacy in human subjects remain to be determined and will necessitate rigorous clinical investigation. To facilitate the translation of this research from the laboratory to potential clinical application, the researchers have leveraged the entrepreneurial support ecosystem at UC Berkeley, including initiatives like Nucleate and Berkeley SkyDeck, to establish a company named ReRx Therapeutics. This venture aims to guide the compound through the necessary stages of development toward eventual human testing.
The research received foundational funding from discretionary resources allocated by UC Berkeley, supplemented by contributions from the UCSF Liver Center and the University of Michigan Animal Phenotyping Core. A comprehensive list of additional contributing authors from various institutions, including UC Berkeley, Massachusetts General Hospital, the University of California, San Diego, the Helmholtz Center Munich, and ReRx Therapeutics, has been acknowledged in the study’s publication.
About the Author
